Eton Pharmaceuticals (ETON) Stock Statistics & Valuation Metrics

Eton Pharmaceuticals has a market cap or net worth of $889.98M. The enterprise value is $936.25M.

Eton Pharmaceuticals has 27,392,359 shares outstanding. The number of shares has decreased by -2.65% in one year.

Eton Pharmaceuticals’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is 0.12%.

The current PE Ratio of Eton Pharmaceuticals is 108.3. Eton Pharmaceuticals’s PEG ratio is -7.42.

In the last 12 months, Eton Pharmaceuticals had revenue of 79.95M and earned -4.60M in profits. Earnings per share was -0.17.

In the last 12 months, operating cash flow was 15.84M and capital expenditures -408.00K, giving a free cash flow of 15.43M billion.

Eton Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Eton Pharmaceuticals upcoming earnings date is Aug 6, 2026, TBA (Confirmed).

Eton Pharmaceuticals as a current ratio of 1.57, with Debt / Equity ratio of 40.01%

In the past 12 months, Eton Pharmaceuticals has paid 43.00K in taxes.

Eton Pharmaceuticals EV to EBITDA ratio is 111.78, with an EV/FCF ratio of 45.15.

Eton Pharmaceuticals has $19.66M in cash and marketable securities with $12.25M in debt, giving a net cash position of $7.41M billion.

Gross margin is 54.77%, with operating margin of 0.09%, and net profit margin of -5.75%.

The average price target for Eton Pharmaceuticals is $45.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy